NCT03123965Approved For MarketingNot Applicable
Expanded Access to Glecaprevir/ Pibrentasvir
AbbVie1 site in 1 countryStarted: April 21, 2017Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Not Applicable
- Status
- Approved For Marketing
- Sponsor
- Locations
- 1
Study Overview
Brief Summary
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to glecaprevir/ pibrentasvir prior to approval by the local regulatory agency. Availability will depend on territory eligibility. Participating sites will be added as they apply for and are approved for the EAP. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
Study Design
- Study Type
- Expanded Access
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
Study Sites (1)
Loading locations...
Similar Trials
No Longer Available
Not Applicable
Expanded Access to VeliparibSolid Tumors With Documented BRCA, BARD, or PALB or Other Acceptable DNA Mutations or Anomalies That Are Scientifically SoundTriple Negative Breast Cancer (TNBC)High Grade Serous Ovarian CancerPatients Requiring Veliparib Suspension FormulationNCT03123211AbbVie
No Longer Available
Not Applicable
Expanded Access to Rovalpituzumab TesirineSmall Cell Lung CancerNCT03503890AbbVie
Available
Not Applicable
Expanded Access to UpadacitinibSpondyloarthritisAxial SpondyloarthritisNon-radiographic AxialNon Segmental VitiligoHidradenitis SuppurativaCrohn DiseaseUlcerative ColitisAtopic DermatitisRheumatoid ArthritisPsoriatic ArthritisGiant Cell ArteritisSystemic Lupus ErythematosusAlopecia AreataNCT04159597AbbVie
No Longer Available
Not Applicable
Expanded Access to EpcoritamabLymphomaNCT05692050AbbVie
No Longer Available
Not Applicable
Expanded Access to ElezanumabAcute Spinal Cord Injury (SCI)NCT04278235AbbVie